GLP-1 receptor agonist drugs as a protective factor against chronic kidney disease in patients with type 2 diabetes mellitus
DOI:
https://doi.org/10.33448/rsd-v10i16.23517Keywords:
Diabetes complications; Chronic kidney disease.Abstract
Type 2 diabetes mellitus (DM) develops due to peripheral insulin resistance, tied to secretory pancreatic fatigue, its pathophysiology involves genetic and environmental factors, such as poor diet and sedentary lifestyle. Diabetic patients have a risk factor for the development of microvascular lesions, such as retinopathy, neuropathy, nephropathy. To evaluate how GLP-1 receptor agonists act as a protective factor for chronic kidney disease in patients with type 2 diabetes mellitus. For the survey of articles in the literature, searches were conducted in the following databases: Latin American and Caribbean Literature in Health Sciences (LILACS), Medical Literature Analysis and Retrieval Sistem online (Medline), Scielo, and articles published in the period 2016-2021, in Portuguese, English and Spanish. From the studies, it was possible to perceive the intimate relationship between patients with type 2 DM and chronic kidney disease (CKD) and the nephroprotective function of GLP-1 analogues. As the development of microvascular lesions is usually chronic and silent, these patients should be monitored frequently. For patients with high chances of kidney injury, the use of GLP-1 analogues has been shown to be a great choice, because in addition to hypoglycemic agents they still have nephroprotective factor, through the reduction of the release of cytokines and hormones capable of directly harming renal cells.
References
Aguiar, L. K. D., Prado, R. R., Gazzinelli, A., & Malta, D. C. (2020). Fatores associados à doença renal crônica: inquérito epidemiológico da Pesquisa Nacional de Saúde. Revista Brasileira de Epidemiologia, 23.
Bertonhi¹, L. G., & Dias, J. C. R. (2018). Diabetes mellitus tipo 2: aspectos clínicos, tratamento e conduta dietoterápica. Revista Ciências Nutricionais Online, 2(2), 1-10.
Carvalho, D. et al. (2016) Agonistas dos Receptores do GLP-1 no Tratamento da Diabetes Tipo 2. Revista Portuguesa de Diabetes, 11 (4), 154-166.
Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., ... & Umpierrez, G. E. (2016). Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes care, 39(2), 222-230.
Davies, M. J.; et al. (2016) Efficacy and safety of liraglutide versus placebo as add-on to glucoselowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRARENAL): a randomized clinical trial. Diabetes care, 39 (2), 222-230.
De Luccia, N. (2020). Doença vascular e diabetes. Jornal Vascular Brasileiro, 2(1), 49-60.
do Vale, V. A. L., Santos, G. M. R., de Freitas, A. A., Araruna, C. C. R. L., Dornelas, E. H. B., de Miranda, G. S. F., & de Sousa, M. B. (2020). Impactos do tratamento com liraglutida na progressão da doença renal crônica em pacientes com diabetes mellitus tipo 2. Brazilian Journal of Health Review, 3(4), 11106-11119.
dos Santos, B. P., Oliveira, V. A., Soares, M. C., & Schwartz, E. (2017). Doença renal crônica: relação dos pacientes com a hemodiálise. ABCS Health Sciences, 42(1).
Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell metabolism, 27(4), 740-756.
Félix, N. D. D. C., & Nóbrega, M. M. L. D. (2019). Síndrome metabólica: análise conceitual no contexto da enfermagem. Revista Latino-Americana de Enfermagem, 27.
Ferreira, A.; et al. (2019) Treatment options for type 2 diabetes mellitus in patients with chronic kidney disease-old and new drugs. Portuguese Journal of Nephrology & Hypertension, 33 (2), 98-106.
Fonseca, K. P., & Abi Rached, C. D. (2019). Complicações do diabetes mellitus. International Journal of Health Management Review, 5(1).
Geloneze, B., de Lima-Júnior, J. C., & Velloso, L. A. (2017). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the brain–adipocyte axis. Drugs, 77(5), 493.
Gómez-Huelgas, R., Martínez-Castelao, A., Artola, S., Górriz, J. L., Menéndez, E., & en nombre del Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica (2014).
Tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica [Treatment of type 2 diabetes mellitus in patients with chronic kidney disease. Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica]. Medicina clinica, 142(2), https://doi.org/10.1016/j.medcli.2013.10.011
Górriz, J. L.; et al. (2020) GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. Journal of Clinical Medicine, 9 (4), 947.
Gross, J. L., Silveiro, S. P., Camargo, J. L., Reichelt, A. J., & Azevedo, M. J. D. (2002). Diabetes melito: diagnóstico, classificação e avaliação do controle glicêmico. Arquivos Brasileiros de Endocrinologia & Metabologia, 46, 16-26.
Hinnen, D. (2017) Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectrum, 30 (3), 202-210.
Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017). Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: a systematic review and mixed‐treatment comparison analysis. Diabetes, Obesity and Metabolism, 19(4), 524-536.
Kawanami, D., & Takashi, Y. (2020). GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms. Frontiers in Pharmacology, 11, 967.
Lira, J. C. G., Oliveira, J. F. D. S. F., Souza, M. A. D., Araújo, M. F. M. D., Damasceno, M. M. C., & Freitas, R. W. J. F. D. (2018). Prevalência da síndrome metabólica e de seus componentes em pessoas com diabetes mellitus tipo 2. Texto & Contexto-Enfermagem, 27.
Mann, J. F., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., & Buse, J. B. (2017). Liraglutide and renal outcomes in type 2 diabetes. New England Journal of Medicine, 377(9), 839-848.
Moraes, L. L., dos Santos, A. L. G., Dias, L. P. P., de Almeida Oliveira, D., Mafra, D., & da Silva Martins, I. C. V. (2017). Identificação de risco cardiovascular pela razão triglicerídeo/HDL-colesterol em pacientes com doença renal crônica em hemodiálise. Scientia Medica, 27(3), ID27369-ID27369.
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22.
Ribeiro, D. L., da Silva, C. M. B., & Barroso, M. G. (2021). Impactos Da Síndrome Metabólica Na Adolescência E Na Puberdade: Revisão Da Literatura. Revista Ciência e Estudos Acadêmicos de Medicina, 1(14).
Rossaneis, M. A., Andrade, S. M. D., Gvozd, R., Pissinati, P. D. S. C., & Haddad, M. D. C. L. (2019). Fatores associados ao controle glicêmico de pessoas com diabetes mellitus. Ciência & Saúde Coletiva, 24, 997-1005.
Sarmento, L. R., Fernandes, P. F. C. B. C., Pontes, M. X., Correia, D. B. S., Chaves, V. C. B., Carvalho, C. F. D. A., ... & Moliterno, L. A. A. (2018). Prevalência das causas primárias de doença renal crônica terminal (DRCT) validadas clinicamente em uma capital do Nordeste brasileiro. Brazilian Journal of Nephrology, 40, 130-135.
Silveira, D. L. D. (2020). Relação entre o número de dentes e a qualidade da alimentação no controle glicêmico de pacientes com diabetes tipo 2.
Sloan, L. A. (2019). Review of glucagon‐like peptide‐1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. Journal of diabetes, 11(12), 938-948.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Izabely Lima Assunção; Giuliana Maria Morais Gonzalez; Vanessa Marques da Silva; Clara Simplício Viana de Carvalho ; Arlene Gama Matos Machado; Victor Martins dos Santos; Gabriela de Abreu Pascoal; Giovanna Oliveira Forest; Jaynnara Caroline Ferreira de Sousa; Isabel Alice Ramos Fonseca; Luciana Sousa Silva; Laís Pereira Mendes; Amanda Pereira Mendes ; Filipe Augusto Lopes Cajubá de Britto; Thassia Almeida Matos Viana; Maria Caroline Leal Borges de Araújo ; Yvilla Cristina Costa; Victoria Alves do Nascimento; Laura Felipe Meinertz ; Gabriel Machado Chiacchio ; Matheus Medeiros Costa; Amanda Mendonça Vieira Cipriano; Daniel Geovane Silva Souza ; Lethícia Maria Morais Gonzalez ; Glória Maria Grangeiro Ferreira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
